LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma

Jie Wu(Union Hospital), Xuejun Hu(First Hospital of China Medical University), Jianfei Qi(University of Maryland, Baltimore), Wanxia Fang(First Hospital of China Medical University), Xiaofang Che(First Hospital of China Medical University), Yizhe Wang(First Hospital of China Medical University), Yang Cheng(First Hospital of China Medical University), Ce Li(Affiliated Hospital of Hebei University), Yue Jin(Peking University), Kezuo Hou(First Hospital of China Medical University), Yunpeng Liu(Shenyang Institute of Automation), Xiujuan Qu(First Hospital of China Medical University), Zichang Yang(First Hospital of China Medical University), Chunlei Zheng(First Hospital of China Medical University)
Biomarker Research
January 30, 2021
10.1186/s40364-021-00262-3
Cited by 45

Related Papers

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021
|Cancer Communications|2021|657
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2022|417